meta-analytical optimization of plga molecular weight in plga-vancomycin capsules for staphylococcus aureus-caused biofilm prevention and eradication

Osteomyelitis is a bone infectious disease that is mainly caused by staphylococcus aureus bacteria. poly lactic-co-glycolic acid (plga)-vancomycin drug-carrier pair is a well-established drug delivery agent to act against this bacterium. this study implemented a combined method of meta-analysis and design-of-experiments (doe) to optimize the plga molecular weight of plga-van systems for staphylococcus aureus-caused biofilm prevention and eradication. the criteria of success were assigned to be the drug concentrations of 2-8 μg/ml in the burst phase of release. it was concluded that higher molecular weights are needed for effective treatment by increasing the lactide-to-glycolide (la/ga) ratio.